HER2阳性-话题@MedSci

#HER2阳性#

183篇内容 | 4823人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1308469, encodeId=d4021308469dc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期, objectType=article, longId=48932, objectId=982548932ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=982548932ef, replyNumber=0, likeNumber=77, createdTime=2015-04-04, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=982548932ef, moduleTitle=NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=982548932ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308468, encodeId=d1ec13084684e, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=2023年HER2阳性乳腺癌市场将达126亿美元, objectType=article, longId=41388, objectId=db354138889, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db354138889, replyNumber=0, likeNumber=72, createdTime=2014-10-19, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db354138889, moduleTitle=2023年HER2阳性乳腺癌市场将达126亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db354138889)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308467, encodeId=5ec7130846e27, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=2023年HER2阳性乳腺癌市场将达到126亿美元, objectType=article, longId=41282, objectId=26284128272, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26284128272, replyNumber=0, likeNumber=59, createdTime=2014-10-17, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26284128272, moduleTitle=2023年HER2阳性乳腺癌市场将达到126亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26284128272)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308466, encodeId=2831130846667, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=ASCO 2014：曲妥珠单抗是HER2阳性早期乳腺癌辅助治疗的标准(ALTTO研究), objectType=article, longId=36148, objectId=d495361484d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d495361484d, replyNumber=0, likeNumber=0, createdTime=2014-06-10, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d495361484d, moduleTitle=ASCO 2014：曲妥珠单抗是HER2阳性早期乳腺癌辅助治疗的标准(ALTTO研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d495361484d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308465, encodeId=4247130846507, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=JCO：T-DM1联合帕妥珠单抗用于晚期HER2阳性乳腺癌靶向治疗, objectType=article, longId=35043, objectId=e2493504371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2493504371, replyNumber=0, likeNumber=0, createdTime=2014-05-22, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2493504371, moduleTitle=JCO：T-DM1联合帕妥珠单抗用于晚期HER2阳性乳腺癌靶向治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2493504371)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308464, encodeId=1727130846408, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Puma制药neratinib用于HER2阳性乳腺癌疗效优于罗氏赫赛汀, objectType=article, longId=33006, objectId=1aa333006b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1aa333006b4, replyNumber=0, likeNumber=0, createdTime=2014-04-10, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1aa333006b4, moduleTitle=Puma制药neratinib用于HER2阳性乳腺癌疗效优于罗氏赫赛汀, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1aa333006b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308463, encodeId=899b1308463a2, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=PLoS One：天然药物补骨脂素能定向攻击HER2阳性乳腺癌细胞, objectType=article, longId=31387, objectId=9ef23138ec8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ef23138ec8, replyNumber=0, likeNumber=59, createdTime=2014-03-04, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ef23138ec8, moduleTitle=PLoS One：天然药物补骨脂素能定向攻击HER2阳性乳腺癌细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ef23138ec8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308462, encodeId=d14d1308462d3, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=ESMO 2013:T-DM1可以使晚期HER2阳性乳腺癌二线治疗获益(TH3RESA研究）, objectType=article, longId=27180, objectId=0e472e180a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e472e180a3, replyNumber=0, likeNumber=81, createdTime=2013-11-29, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e472e180a3, moduleTitle=ESMO 2013:T-DM1可以使晚期HER2阳性乳腺癌二线治疗获益(TH3RESA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e472e180a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308459, encodeId=4f7f1308459de, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=曲妥珠单抗用于HER2阳性胃癌的治疗病例解析及思考, objectType=article, longId=21786, objectId=571b21e8663, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=571b21e8663, replyNumber=0, likeNumber=83, createdTime=2013-07-21, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=571b21e8663, moduleTitle=曲妥珠单抗用于HER2阳性胃癌的治疗病例解析及思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=571b21e8663)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308460, encodeId=60ca1308460b4, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=病例分享：HER2阳性胃癌治疗及思考, objectType=article, longId=21800, objectId=d8c321800b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8c321800b4, replyNumber=0, likeNumber=73, createdTime=2013-07-21, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8c321800b4, moduleTitle=病例分享：HER2阳性胃癌治疗及思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8c321800b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308461, encodeId=27fb13084614f, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=病例分享：HER2阳性晚期胃癌治疗方案, objectType=article, longId=21802, objectId=e03721802cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e03721802cb, replyNumber=0, likeNumber=77, createdTime=2013-07-21, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e03721802cb, moduleTitle=病例分享：HER2阳性晚期胃癌治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e03721802cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308458, encodeId=a712130845841, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet Oncol：12个月曲妥珠单抗治疗仍是HER2阳性早期乳腺癌患者的标准方案, objectType=article, longId=20927, objectId=f5f32092e78, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5f32092e78, replyNumber=0, likeNumber=72, createdTime=2013-07-06, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5f32092e78, moduleTitle=Lancet Oncol：12个月曲妥珠单抗治疗仍是HER2阳性早期乳腺癌患者的标准方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5f32092e78)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308457, encodeId=d172130845e7c, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=CHMP建议批准罗氏皮下注射剂型Herceptin用于HER2阳性乳腺癌, objectType=article, longId=20872, objectId=597b208e219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=597b208e219, replyNumber=0, likeNumber=84, createdTime=2013-07-05, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=597b208e219, moduleTitle=CHMP建议批准罗氏皮下注射剂型Herceptin用于HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=597b208e219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308456, encodeId=b9091308456df, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet Oncol：帕妥珠单抗、曲妥珠单抗和多烯紫杉醇方案可作为HER2阳性的转移性乳腺癌患者的标准治疗方案, objectType=article, longId=18507, objectId=75c41850e4b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75c41850e4b, replyNumber=0, likeNumber=64, createdTime=2013-05-11, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75c41850e4b, moduleTitle=Lancet Oncol：帕妥珠单抗、曲妥珠单抗和多烯紫杉醇方案可作为HER2阳性的转移性乳腺癌患者的标准治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75c41850e4b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308455, encodeId=a76a13084553c, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Clin Cancer Res. ：在HER2阴性乳腺癌中鉴定出HER2阳性干细胞, objectType=article, longId=18292, objectId=0fad1829240, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fad1829240, replyNumber=0, likeNumber=88, createdTime=2013-05-08, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fad1829240, moduleTitle=Clin Cancer Res. ：在HER2阴性乳腺癌中鉴定出HER2阳性干细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fad1829240)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308454, encodeId=03e41308454b9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=Lancet Oncol：拉帕替尼可使早期HER2阳性乳腺癌患者获益, objectType=article, longId=13716, objectId=601413e16ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=601413e16ad, replyNumber=0, likeNumber=58, createdTime=2012-12-28, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=601413e16ad, moduleTitle=Lancet Oncol：拉帕替尼可使早期HER2阳性乳腺癌患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=601413e16ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308453, encodeId=6fcd1308453b1, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性晚期胃癌分子靶向治疗中国专家共识, objectType=article, longId=10845, objectId=2cbd1084525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cbd1084525, replyNumber=0, likeNumber=67, createdTime=2012-11-09, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cbd1084525, moduleTitle=HER2阳性晚期胃癌分子靶向治疗中国专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cbd1084525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308452, encodeId=8e4d1308452ba, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性晚期胃癌分子靶向治疗中国专家共识, objectType=article, longId=7423, objectId=96a9e42329, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96a9e42329, replyNumber=0, likeNumber=61, createdTime=2012-06-28, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96a9e42329, moduleTitle=HER2阳性晚期胃癌分子靶向治疗中国专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96a9e42329)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308451, encodeId=b85d1308451ac, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=《HER2阳性晚期胃癌分子靶向治疗中国专家共识》草案摘要, objectType=article, longId=7132, objectId=47c5e132c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47c5e132c6, replyNumber=0, likeNumber=69, createdTime=2012-06-19, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47c5e132c6, moduleTitle=《HER2阳性晚期胃癌分子靶向治疗中国专家共识》草案摘要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47c5e132c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308450, encodeId=0505130845064, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=ASCO:T-DM1治疗进展期HER2阳性乳腺癌优于卡培他滨+拉帕替尼, objectType=article, longId=6777, objectId=f36c6e7786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f36c6e7786, replyNumber=0, likeNumber=0, createdTime=2012-06-07, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f36c6e7786, moduleTitle=ASCO:T-DM1治疗进展期HER2阳性乳腺癌优于卡培他滨+拉帕替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f36c6e7786)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阳性

2020-05-29

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

NEJM：帕妥珠单抗，曲妥珠单抗和多西他赛联合用药：提高HER2阳性转移性乳腺癌患者总体生存期

2015-04-04

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

2023年HER2阳性乳腺癌市场将达126亿美元

2014-10-19

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

2023年HER2阳性乳腺癌市场将达到126亿美元

2014-10-17

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

ASCO 2014：曲妥珠单抗是HER2阳性早期乳腺癌辅助治疗的标准(ALTTO研究)

2014-06-10

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

JCO：T-DM1联合帕妥珠单抗用于晚期HER2阳性乳腺癌靶向治疗

2014-05-22

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Puma制药neratinib用于HER2阳性乳腺癌疗效优于罗氏赫赛汀

2014-04-10

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

PLoS One：天然药物补骨脂素能定向攻击HER2阳性乳腺癌细胞

2014-03-04

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

ESMO 2013:T-DM1可以使晚期HER2阳性乳腺癌二线治疗获益(TH3RESA研究）

2013-11-29

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

曲妥珠单抗用于HER2阳性胃癌的治疗病例解析及思考

2013-07-21

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

病例分享：HER2阳性胃癌治疗及思考

2013-07-21

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

病例分享：HER2阳性晚期胃癌治疗方案

2013-07-21

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet Oncol：12个月曲妥珠单抗治疗仍是HER2阳性早期乳腺癌患者的标准方案

2013-07-06

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

CHMP建议批准罗氏皮下注射剂型Herceptin用于HER2阳性乳腺癌

2013-07-05

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet Oncol：帕妥珠单抗、曲妥珠单抗和多烯紫杉醇方案可作为HER2阳性的转移性乳腺癌患者的标准治疗方案

2013-05-11

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Clin Cancer Res. ：在HER2阴性乳腺癌中鉴定出HER2阳性干细胞

2013-05-08

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

Lancet Oncol：拉帕替尼可使早期HER2阳性乳腺癌患者获益

2012-12-28

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性晚期胃癌分子靶向治疗中国专家共识

2012-11-09

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性晚期胃癌分子靶向治疗中国专家共识

2012-06-28

医者仁心 (审核中...)

前往app查看评论内容

#HER2阳性#

《HER2阳性晚期胃癌分子靶向治疗中国专家共识》草案摘要

2012-06-19

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

ASCO:T-DM1治疗进展期HER2阳性乳腺癌优于卡培他滨+拉帕替尼

2012-06-07

科室
- - 订阅+
  - 更多科室
工具
服务